Citations 2
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation
Kanate, Abraham S. , Kumar, Ambuj , Dreger, Peter , Dreyling, Martin, Gouill, Steven Le , Bredeson, Christopher , Fenske, Timothy S. , Smith, Sonali M. , Sureda, Anna , Moskowitz, Alison J. , Friedberg, Jonathan W. , Inwards, David J. , Herrera, Alex F. , Kharfan‐Dabaja, Mohamed A. , Reddy, Nishitha , Montoto, Silvia , Abutalib, Syed A., Gisselbrecht, Christian , Carpenter, Paul A. , Kharfan-Dabaja, Mohamed A., Montoto, Silvia , Dreyling, Martin, Corradini, Paolo , Robinson, Stephen Paul , Vose, Julie M. , Gopal, Ajay K. , Shadman, Mazyar , Perales, Miguel‐Angel , Savani, Bipin N. , Hamadani, Mehdi
JAMA Oncology | February 28, 2019 | Volume: 5 | Issue: 5 | Pages: 715
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease
Martin, Paul J. , Storer, Barry E. , Inamoto, Yoshihiro , Carpenter, Paul A. , Pidala, Joseph, Palmer, Jeanne , Arora, Mukta , Jagasia, Madan , Arai, Sally , Lee, Stephanie J. , Flowers, Mary E.D. , Cutler, Corey S. , Lee, Stephanie J
Blood | May 11, 2017 | Volume: 130 | Issue: 3 | Pages: 360-367
Key Points Complete or partial response at 1 year without secondary systemic treatment provides clinical benefit in patients with chronic GVHD. Success defined by this endpoint is currently observed in fewer than 20% of patients after initial systemic treatment of chronic GVHD.